---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-227940"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:16:08.350736+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA lifts clinical hold on Biomea Fusion's BMF-219 for type 2 and type 1 diabetes trials

## Summary
- FDA lifted clinical hold on Phase I/II trials COVALENT-111 (type 2 diabetes) and COVALENT-112 (type 1 diabetes) as of Sept 26, 2024.
- CEO stated safety signals from Phase 2a Escalation Study did not translate to Phase 2b Expansion Study; no confirmed serious liver injury.
- Company expects to announce a third development candidate (oral GLP-1 agonist) in Q4 2024.
- Topline Week 26 data from ~200-patient Phase 2b COVALENT-111 and Phase 2a COVALENT-112 (20 patients) expected Q4 2024.

## SEC filing metadata
- accession: 0001193125-24-227940
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312524227940/0001193125-24-227940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312524227940/d310466d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-227940
- JSON: https://secwatch.observer/filing/0001193125-24-227940.json
- Plain text: https://secwatch.observer/filing/0001193125-24-227940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.